Last reviewed · How we verify

Ocuzolin — Competitive Intelligence Brief

Ocuzolin (tetryzoline) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tetryzoline. Area: Ophthalmology.

marketed tetryzoline Adrenergic receptor alpha Ophthalmology Live · refreshed every 30 min

Target snapshot

Ocuzolin (tetryzoline) — Fougera Pharms.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ocuzolin TARGET tetryzoline Fougera Pharms marketed tetryzoline Adrenergic receptor alpha 1979-01-01
Aldomet METHYLDOPATE Merck & Co. marketed Adrenergic receptor alpha-2 1962-01-01
Levonordefrin corbadrine Eastman Kodak marketed corbadrine Alpha-1D adrenergic receptor, Adrenergic receptor alpha-2, Adrenergic receptor alpha-1 1960-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tetryzoline class)

  1. Fougera Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ocuzolin — Competitive Intelligence Brief. https://druglandscape.com/ci/tetryzoline. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: